- Home
- NRDS vs GHRS Comparison
NRDS vs GHRS Comparison
Compare NRDS & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRDS
- GHRS
- Stock Information
- Founded
- NRDS 2009
- GHRS 2018
- Country
- NRDS United States
- GHRS Ireland
- Employees
- NRDS N/A
- GHRS N/A
- Industry
- NRDS EDP Services
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- NRDS Technology
- GHRS Health Care
- Exchange
- NRDS Nasdaq
- GHRS Nasdaq
- Market Cap
- NRDS 1.0B
- GHRS 868.7M
- IPO Year
- NRDS 2021
- GHRS 2021
- Fundamental
- Price
- NRDS $10.33
- GHRS $12.51
- Analyst Decision
- NRDS Buy
- GHRS Strong Buy
- Analyst Count
- NRDS 5
- GHRS 3
- Target Price
- NRDS $17.60
- GHRS $35.67
- AVG Volume (30 Days)
- NRDS 617.6K
- GHRS 1.1M
- Earning Date
- NRDS 02-19-2025
- GHRS 02-27-2025
- Dividend Yield
- NRDS N/A
- GHRS N/A
- EPS Growth
- NRDS N/A
- GHRS N/A
- EPS
- NRDS 0.38
- GHRS N/A
- Revenue
- NRDS $687,600,000.00
- GHRS N/A
- Revenue This Year
- NRDS $14.44
- GHRS N/A
- Revenue Next Year
- NRDS $13.10
- GHRS N/A
- P/E Ratio
- NRDS $27.42
- GHRS N/A
- Revenue Growth
- NRDS 14.71
- GHRS N/A
- 52 Week Low
- NRDS $10.10
- GHRS $6.00
- 52 Week High
- NRDS $17.30
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- NRDS 21.71
- GHRS 51.44
- Support Level
- NRDS $13.25
- GHRS $13.50
- Resistance Level
- NRDS $14.45
- GHRS $14.91
- Average True Range (ATR)
- NRDS 0.75
- GHRS 1.58
- MACD
- NRDS -0.36
- GHRS -0.22
- Stochastic Oscillator
- NRDS 3.38
- GHRS 5.56
About NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides onsumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. They get revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.